Pfizer Inc. (NYSE:PFE) Receives $36.88 Average PT from Brokerages

Shares of Pfizer Inc. (NYSE:PFEGet Free Report) have been assigned an average rating of “Hold” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $36.88.

PFE has been the topic of several research reports. UBS Group reduced their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Truist Financial dropped their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Barclays decreased their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company.

Get Our Latest Stock Analysis on PFE

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average price of $26.47 per share, for a total transaction of $79,410.00. Following the transaction, the director now owns 9,000 shares in the company, valued at approximately $238,230. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is currently owned by company insiders.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RB Capital Management LLC lifted its stake in shares of Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. increased its holdings in Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank increased its holdings in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC increased its holdings in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after acquiring an additional 79,887 shares during the last quarter. Hedge funds and other institutional investors own 68.05% of the company’s stock.

Pfizer Trading Up 4.2 %

Shares of PFE stock opened at $28.37 on Friday. The company’s 50-day moving average price is $27.76 and its 200-day moving average price is $30.07. Pfizer has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $160.17 billion, a price-to-earnings ratio of 78.79, a PEG ratio of 1.22 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, equities analysts predict that Pfizer will post 2.22 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 1st. Stockholders of record on Friday, January 26th were given a $0.42 dividend. The ex-dividend date of this dividend was Thursday, January 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.92%. This is a boost from Pfizer’s previous quarterly dividend of $0.41. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Pfizer Company Profile

(Get Free Report

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.